We are live on
!
Find out more
PM
Penbrook Management Portfolio holdings
AUM
$157M
1-Year Est. Return
46.57%
This Fund
S&P 500
This Quarter
Est. Return
+11.99%
1 Year Est. Return
+46.57%
3 Year Est. Return
+102.93%
5 Year Est. Return
+150.44%
10 Year Est. Return
–
AUM
$103M
AUM Growth
–
Cap. Flow
+$98.2M
Cap. Flow
% of AUM
95.28%
Top 10 Holdings %
Top 10 Hldgs %
26.91%
Holding
111
New
111
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVO
Novo Nordisk
NVO
|
+$4.43M |
| 2 |
Microsoft
MSFT
|
+$2.97M |
| 3 |
FEIC
FEI COMPANY
FEIC
|
+$2.86M |
| 4 |
Harvard Bioscience
HBIO
|
+$2.45M |
| 5 |
Calumet Specialty Products
CLMT
|
+$2.34M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.65% |
| 2 | Healthcare | 15.42% |
| 3 | Energy | 13.56% |
| 4 | Financials | 12.08% |
| 5 | Industrials | 6% |
Similar funds
IWM
EP
AC
SF
LAM
HAM
HEM
CF
Penbrook Management's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Penbrook Management, which disclosed 111 positions worth $103M. Its ten largest holdings account for 27% of the portfolio.
Its largest position is Novo Nordisk: 254,000 shares worth $4.69M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, followed by Healthcare and Energy.
- Penbrook Management's largest Q4 2013 buy was Novo Nordisk: 254,000 shares worth $4.69M.
- Penbrook Management's ten largest holdings make up 27% of its $103M portfolio in Q4 2013.
- Penbrook Management disclosed 111 positions in Q4 2013, its first 13F filing on record.
Based on Penbrook Management's 13F filing for Q4 2013, filed 25 Mar 2014.